Welcome to our dedicated page for ARCELLX news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on ARCELLX stock.
Arcellx, Inc. developed cell therapies and immunotherapies for cancer and other incurable diseases, with company news centered on anitocabtagene autoleucel, or anito-cel, an investigational BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Coverage included clinical data from the iMMagine program, scientific presentations on the D-Domain binder, and collaboration activity with Kite, a Gilead company.
Arcellx became a wholly owned subsidiary of Gilead Sciences after the completed acquisition in 2026, and its common stock was delisted from the Nasdaq Global Select Market. Later company developments therefore include the completed transaction, shareholder-related deal coverage, capital-structure matters, and public-company status changes.
Arcellx, Inc. (NASDAQ: ACLX) announced participation by CEO Rami Elghandour and CMO Chris Heery in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 4:50 p.m. E.T. The discussion will be accessible via a live webcast on Arcellx's website, with a replay available for 30 days post-event. The company is focused on advancing cell therapies, particularly CART-ddBCMA for relapsed or refractory multiple myeloma, and is progressing ARC-SparX for acute myeloid leukemia. Both product candidates have received various FDA designations.
Arcellx, Inc. (NASDAQ: ACLX) announced the presentation of pre-clinical data for ACLX-002, a CD123-targeted CAR-T cell therapy aimed at treating relapsed or refractory Acute Myeloid Leukemia (AML), at the American Association for Cancer Research Annual Meeting 2022. ACLX-002 offers controllability through a dose-dependent activation mechanism, addressing patient-specific disease variations and reducing the risk of adverse events. The presentation is scheduled for April 10, 2022, at the New Orleans Convention Center, highlighting the company's commitment to advancing innovative cancer therapies.
Arcellx, Inc. (NASDAQ: ACLX) successfully closed its initial public offering, selling 9,487,500 shares of common stock at a public offering price of $15.00 per share, generating aggregate gross proceeds of $142.3 million. The offering included an additional 1,237,500 shares purchased by underwriters. The stock began trading on the Nasdaq Global Select Market on February 4, 2022. The offering was managed by BofA Securities, SVB Leerink, Barclays, and William Blair, with a registration statement filed with the SEC becoming effective on February 3, 2022.
Arcellx, a clinical-stage biotechnology company, has announced the pricing of its initial public offering (IPO) of 8,250,000 shares at $15.00 each, aiming for gross proceeds of approximately $123.8 million. The IPO shares will commence trading on the Nasdaq under the ticker symbol ACLX on February 4, 2022, with the offering expected to close on February 8, 2022. An additional 1,237,500 shares may be purchased by underwriters. The company focuses on innovative immunotherapies for cancer and has received multiple FDA designations for its lead product candidate.